Silence Therapeutics (SLN) Cash from Investing Activities (2020 - 2026)

Silence Therapeutics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at $10.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 122.53% year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $6.4 million (up 142.49% YoY), while the FY2025 annual figure was -$48.0 million, down 118.48% from the prior year.
• Cash from Investing Activities came in at $10.0 million for Q1 2026 at Silence Therapeutics, up from -$53.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $66.1 million in Q4 2024 to a low of -$53.3 million in Q4 2025.
• A 5-year average of -$3.4 million and a median of -$49499.0 in 2022 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities jumped 52887.25% in 2023 and plunged 32177.6% in 2024, its largest moves.
• Silence Therapeutics' Cash from Investing Activities stood at -$19.3 million in 2022, then jumped by 102.46% to $474120.0 in 2023, then soared by 13846.89% to $66.1 million in 2024, then tumbled by 180.66% to -$53.3 million in 2025, then jumped by 118.75% to $10.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $10.0 million, -$53.3 million, and $51.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison